Journal of Gastrointestinal Cancer

, Volume 45, Issue 3, pp 307–311

Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites: an Interim Analysis

  • Naminatsu Takahara
  • Hiroyuki Isayama
  • Yousuke Nakai
  • Takashi Sasaki
  • Hironori Ishigami
  • Hiroharu Yamashita
  • Hironori Yamaguchi
  • Tsuyoshi Hamada
  • Rie Uchino
  • Suguru Mizuno
  • Koji Miyabayashi
  • Dai Mohri
  • Kazumichi Kawakubo
  • Hirofumi Kogure
  • Natsuyo Yamamoto
  • Naoki Sasahira
  • Kenji Hirano
  • Hideaki Ijichi
  • Keisuke Tateishi
  • Minoru Tada
  • Joji Kitayama
  • Toshiaki Watanabe
  • Kazuhiko Koike
Original Research

DOI: 10.1007/s12029-014-9603-1

Cite this article as:
Takahara, N., Isayama, H., Nakai, Y. et al. J Gastrointest Canc (2014) 45: 307. doi:10.1007/s12029-014-9603-1

Abstract

Objectives

Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites.

Methods

Paclitaxel was administered intravenously at 50 mg/m2 and intraperitoneally at 20 mg/m2 on days 1 and 8 every 3 weeks, and S-1 was administered at 80 mg/m2/day for 14 consecutive days, followed by 7-day rest.

Results

Between April 2011 and February 2012, ten patients were enrolled. A partial response was achieved in two patients (20 %) and a disease control rate of 50 %. The median time to progression and overall survival were 2.1 and 3.4 months, respectively. Malignant ascites was completely resolved in two patients (20 %). Major grade 3/4 adverse events were myelosuppression including neutropenia (50 %) and catheter-related infection (10 %).

Conclusions

This novel combination chemotherapy was feasible and showed promising results in pancreatic cancer patients with malignant ascites (clinical trial registration number: UMIN000005306).

Keywords

Pancreatic cancer Malignant ascites S-1 Paclitaxel Intraperitoneal chemotherapy 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Naminatsu Takahara
    • 1
  • Hiroyuki Isayama
    • 1
  • Yousuke Nakai
    • 1
  • Takashi Sasaki
    • 1
  • Hironori Ishigami
    • 2
    • 3
  • Hiroharu Yamashita
    • 3
  • Hironori Yamaguchi
    • 3
  • Tsuyoshi Hamada
    • 1
  • Rie Uchino
    • 1
  • Suguru Mizuno
    • 1
  • Koji Miyabayashi
    • 1
  • Dai Mohri
    • 1
  • Kazumichi Kawakubo
    • 1
  • Hirofumi Kogure
    • 1
  • Natsuyo Yamamoto
    • 1
  • Naoki Sasahira
    • 1
  • Kenji Hirano
    • 1
  • Hideaki Ijichi
    • 1
  • Keisuke Tateishi
    • 1
  • Minoru Tada
    • 1
  • Joji Kitayama
    • 3
  • Toshiaki Watanabe
    • 3
  • Kazuhiko Koike
    • 1
  1. 1.Department of Gastroenterology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of Outpatient ChemotherapyThe University of TokyoTokyoJapan
  3. 3.Department of Surgical OncologyThe University of TokyoTokyoJapan

Personalised recommendations